# A study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD (chronic obstructive pulmonary disease) patients with Type 2 inflammation.

URL: https://www.renown.org/clinical-trials-directory/7402511225

Short Title: Vigilant

Enrollment Status: Recruiting

NCT #: [NCT07177339](https://clinicaltrials.gov/study/NCT07177339)

Specialty Area: Pulmonology

Condition Studied: Chronic Obstructive Pulmonary Disease

Age Groups: Adult; Older Adult

Sex: All

Study Type: Interventional

Accepts Healthy Volunteers: No

Phase: III

Principal Investigator: Farah Madhani-Lovely, MD

Complete Study Details: https://clinicaltrials.gov/study/NCT07177339

## Study Information

### Summary / Purpose

To assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.

### Who Can Participate

- Adults 40-75 years of age
- Clinically documented history of COPD for at least 1 year
- Have had one COPD exacerbation in the last 12 months
- Current or former smoker with history of > 10 pack-years
- Optimized dual or triple inhaler therapy
- A post-salbutamol forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio of less than (\<)0.70 and a post-salbutamol FEV1 greater than (>)30 percent (%) and \<80% predicted normal values

### What's Involved

- Administration of the study medication
- Spirometry test to measure airflow and lung capacity
- Collection of a mucus sample from the lower airways (induced sputum)
- Maintaining an E-diary
- Completing health outcome assessments
- Electrocardiogram (ECG)
- Lab draw
- High resolution computed tomography
- Magnetic resonance imaging (MRI)

## Additional Information

Location: Renown Health, Office of Clinical Research

Address: 1500 E 2nd St. Reno, NV 89502

General Research: [775-982-3646](tel:775-982-3646)

Oncology Research: [775-982-5050](tel:775-982-5050)

Email: [Renown-CRD@renown.org](mailto:Renown-CRD@renown.org)
